Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Hong Kong Stock Exchange  >  Shanghai Henlius Biotech, Inc.    2696   CNE100003N76

SHANGHAI HENLIUS BIOTECH, INC.

(2696)
  Report
 SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   End-of-day quote. End-of-day quote Hong Kong Stock Exchange
10/19/2020 10/20/2020 10/21/2020 10/22/2020 10/23/2020 Date
43.1 43 42.75 41.6 40.95 Last
184600 59400 102700 77615 53486 Volume
-4.43% -0.23% -0.58% -2.69% -1.56% Change
Financials
Sales 2020 639 M 95,6 M 95,6 M
Net income 2020 -775 M -116 M -116 M
Net Debt 2020 1 091 M 163 M 163 M
P/E ratio 2020 -27,9x
Yield 2020 -
Sales 2021 1 583 M 237 M 237 M
Net income 2021 -433 M -64,8 M -64,8 M
Net cash position 2021 652 M 97,5 M 97,5 M
P/E ratio 2021 -51,6x
Yield 2021 -
Capitalization 22 256 M 2 872 M 3 330 M
EV / Sales 2020 36,5x
EV / Sales 2021 13,7x
Nbr of Employees 1 629
Free-Float 18,8%
More Financials
Company
Shanghai Henlius Biotech Inc. is a China-based company principally involved in the research, development, production and sales of monoclonal antibody products. The Company’s main products include rituximab injection HLX01 (Hanlikang), Herceptin (trastuzumab) biosimilar HLX02, Humira (adalimumab) biosimilar HLX03 and Avastin (bevacizumab) biosimilar HLX04, as well as bio-innovative drug candidates, including HLX06... 
Sector
Pharmaceuticals
Calendar
-
More about the company
Notations Surperformance© of Shanghai Henlius Biotech, Inc.
Trading Rating : Investor Rating :
More Ratings
All news about SHANGHAI HENLIUS BIOTECH, INC.
10/08Fosun unit to begin U.S. trial of COVID-19 antibody treatment soon
RE
09/20SHANGHAI HENLIUS BIOTECH : Voluntary announcement - first patient has been dosed..
PU
09/20SHANGHAI HENLIUS BIOTECH : Voluntary announcement - shanghai henlius issues late..
PU
09/17SHANGHAI HENLIUS BIOTECH : Voluntary announcement - shanghai henlius released th..
PU
09/09SHANGHAI HENLIUS BIOTECH : Voluntary announcement - new drug application of hlx0..
PU
08/28SHANGHAI HENLIUS BIOTECH : Supplemental announcement to the company's 2019 annua..
PU
08/14SHANGHAI HENLIUS BIOTECH : Inside information announcement - new drug applicatio..
PU
08/12SHANGHAI HENLIUS BIOTECH : Voluntary announcement - results of a phase 3 clinica..
PU
07/29SHANGHAI HENLIUS BIOTECH : Voluntary announcement - first patient has been dosed..
PU
07/29INSIDE INFORMATION ANNOUNCEMENT - MA : Zercepac) being approved by the european ..
PU
07/10SHANGHAI HENLIUS BIOTECH : Henlius and Accord Receive Positive CHMP Opinion for ..
AQ
More news
News in other languages on SHANGHAI HENLIUS BIOTECH, INC.

- No features available -

More news
Chart SHANGHAI HENLIUS BIOTECH, INC.
Duration : Period :
Shanghai Henlius Biotech, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends SHANGHAI HENLIUS BIOTECH, INC.
Short TermMid-TermLong Term
TrendsBearishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 12
Average target price 61,77 CNY
Last Close Price 40,95 CNY
Spread / Highest target 76,0%
Spread / Average Target 50,8%
Spread / Lowest Target 25,6%
EPS Revisions
Managers
NameTitle
Wen Jie Zhang President & Chief Executive Officer
Qi Yu Chen Chairman
Rong Li Feng Chairman-Supervisory Board
Zi Dong Zhang Chief Financial Officer
Wei Dong Jiang Chief Scientific Officer & Senior Vice President
Sector and Competitors
1st jan.Capitalization (M$)
SHANGHAI HENLIUS BIOTECH, INC.0.49%2 917
CSL LIMITED6.91%95 866
BIOGEN INC.-10.09%41 056
WUXI BIOLOGICS (CAYMAN) INC.121.59%39 118
SAMSUNG BIOLOGICS CO.,LTD.46.88%38 341
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO.,LTD.189.37%36 623